RE: siRNA writeup10 Apr 2023 18:34
Cheers Leister
As Nigel stated in the latest directors talk interview, their should be multiple items of newsflow to come before the end of June.
siRNA results as they come in for both single loading, double loading ,in-vitro and in-vivo.
The target market for commercial discussions also now much larger with the focus on siRNA as opposed to just vaccine delivery.
Plus the sidelines of oral delivery / viral vectors / gene therapy...
Obviously existing investors have had a rough time but for new investors suddenly it's not looking so bad. 1.7p doesn't look like a bad entry considering the co recently cashed themselves up via the 2p placing.